SV Investment Corp
VC Fund
Seoul, South Korea
SV Investment Corp is a venture capital firm that provides companies with finance, strategic advice and information at critical stages of their development.
- Total investments:
- 112
- Last investment:
- Lead investor:
- 29%
Last updated:
For AI agents: llms.txt
Industries SV Investment Corp invests in
Stages SV Investment Corp invests in
Countries SV Investment Corp invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $1.2M–$31M
- Series A
- $2.8M–$36M
- Series B
- $7.5M–$60M
Investment Focus
Industry
- Software 15 (13%)
- Information Technology 14 (13%)
- Artificial Intelligence 14 (13%)
- Medical 9 (8%)
- Health Care 9 (8%)
Stage
- Series A 38 (34%)
- Series B 28 (25%)
- Seed 16 (14%)
- Series C 11 (10%)
- Venture - Series Unknown 6 (5%)
Country
- South Korea 68 (61%)
- United States 11 (10%)
- China 2 (2%)
- Germany 1 (1%)
- Vietnam 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Jung Kwangha
VP
|
VP | Total investments: 1 | Find email | |
Lee Jae-won
Director
|
Director | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Inserasolution
|
Inserasolution produces high-performance Fast & Fine Steering Mirrors for laser-based space optical communications and sophisticated defense systems. | $9.8M / Series A / Sep 01, 2026 | |
| Kalivir designs safe and potent oncolytic product candidates across multiple tumor types. Kalivir’s cutting-edge, next generation oncolytic viral immunotherapy programs combine technologies developed in-house and licensed from University of Pittsburgh’s world-class oncolytic virus and immunotherapy research programs. | $14M / Series A / Aug 19, 2026 | ||
Linq
|
We are creating ‘hyper-automated insurance platforms’ to comprehensively support underwriters and claim adjusters and to facilitate communication between insurers and reinsurers using AI and deep learning. | $22M / Series A / Jul 02, 2026 | |
| CarbonSix develops AI-powered robotics technologies for manufacturing automation, with a focus on tasks that involve high product variation and changing production conditions. Its platform uses imitation learning to enable industrial robots to learn from human demonstrations and perform complex manipulation tasks that are difficult to automateusing conventional programming methods. The company combines robotics hardware and AI software to improve robot adaptability while meeting industrial quality and reliability requirements. Its solutions are designed for manufacturing environments where flexible automation is needed for assembly and other variable production processes. | $40M / Series A / Jul 01, 2026 | ||
| XCENA is a semiconductor company that develops data-centric computing systems designed for AI and large-scale data processing environments. The company builds computational memory technology that combines high-capacity pooled DDR5 memory with near-data processing capabilities, allowing computation to occur closer to where data is stored. Its coreplatform is based on the Compute Express Link (CXL) standard, which enables memory expansion beyond traditional CPU limitations while improving data movement efficiency and reducing latency in data center workloads. XCENA’s architecture is designed to support applications such as artificial intelligence workloads, vector databases, and large-scale analytics by addressing memory bandwidth and capacity constraints. The company provides a hardware-software ecosystem that includes computational memory systems and a full-stack software development kit. This SDK offers APIs, runtime tools, and drivers that allow applications to use computational memory without major changes to existing software architectures while also supporting low-level control for performance optimization.XCENA’s flagship product line includes MX1, a CXL-based computational memory solution that integrates near-data processing engines with memory infrastructure to support AI inference and data-intensive workloads. The platform is designed to improve throughput and scalability in environments where traditional memory architectures become a bottleneck. The company operates in the broader field of AI infrastructure and memory innovation, working with customers such as hyperscalers, telecom providers, and research institutions that manage large-scale computing workloads. Its solutions are intended to improve efficiency in systems handling AI, big data processing, and scientific computing. | $135M / Series B / May 29, 2026 | ||
| Asteromorph is an artificial intelligence (AI) research startup for the development of scientific superintelligence | $31.3M / Seed / May 29, 2026 | ||
| Caring is a visiting medical treatment facility that offers medical consultation. | $27.3M / Series C / May 08, 2026 | ||
| GenEdit was founded to transform the delivery of gene therapies and enable the next generation of non-viral, gene editing-based therapeutics. GenEdit’s proprietary technology, NanoGalaxy™ platform solves current delivery challenges by systematically screening its nanoparticle library and providing safer and efficient delivery to target tissues. Thecompany's tool makes therapeutic gene editing possible and is easier to use, faster and more accurate than previous gene-editing techniques and thus has the potential for a wide range of therapeutic applications, enabling physicians to cure incurable genetic diseases. | $60M / Series B / Feb 25, 2026 | ||
| AITRICS delivers AI-powered medical software designed to support clinicians in detecting and preventing critical patient deterioration. The company’s core product, AITRICS‑VC (VitalCare), continuously monitors data from electronic medical records (EMRs), including vital signs, lab tests, consciousness levels, and other relevant clinicalmeasurements to predict adverse events such as sepsis, cardiac arrest, unexpected ICU transfers, or mortality several hours before they occur.AITRICS-VC operates in real time, delivering risk scores and alerts to clinicians to enable earlier intervention and better resource allocation in hospital settings. The platform has been certified by the relevant regulatory authority in its home country and is classified as an “innovative medical device,” reflecting regulatory recognition of its predictive-analytics capabilities. In addition to monitoring and prediction, AITRICS engages in ongoing clinical validation and research; it publishes studies in peer-reviewed journals and presents its work in international AI conferences, indicating a commitment to evidence-based development and transparency in performance. | $23.8M / Series C / Dec 01, 2025 | ||
| PineTree Therapeutics engages in the development of disruptive therapies in Oncology and Immuno-oncology. | $47M / Series B / Oct 28, 2025 | ||
| See all 112 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does SV Investment Corp invest in?
SV Investment Corp invests primarily in Software, Information Technology and Artificial Intelligence startups, most often at Series A and Series B stage. Most of the 112 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does SV Investment Corp invest in?
SV Investment Corp typically joins rounds of $1.2M–$31M at Seed, $2.8M–$36M at Series A and $7.5M–$60M at Series B. These are whole funding-round sizes, not SV Investment Corp's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds SV Investment Corp took part in.
How do I contact SV Investment Corp?
Public channels for SV Investment Corp include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at SV Investment Corp?
The team at SV Investment Corp includes Jung Kwangha (VP) and Lee Jae-won (Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
